Literature DB >> 29471019

Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease.

Anand Rane1, Subramanian Rajagopalan1, Manuj Ahuja2, Bobby Thomas2, Shankar J Chinta3, Julie K Andersen4.   

Abstract

The heat shock factor 90 (hsp90) complex has long been associated with neuropathological phenotypes linked to Parkinson's disease (PD) and its inhibition is neuroprotective in disease models. Hsp90 is conventionally believed to act by suppressing induction of hsp70. Here, we report a novel hsp70-independent mechanism by which Hsp90 may also contribute to PD-associated neuropathology. We previously reported that inhibition of the enzyme prolyl hydroxylase domain 2 (PHD2) in conjunction with increases in hypoxia-inducible factor 1 alpha (HIF1α) results in protection of vulnerable dopaminergic substantia nigra pars compacta (DAergic SNpc) neurons in in vitro and in vivo models of PD. We discovered an increased interaction between PHD2 and the p23:Hsp90 chaperone complex in response to mitochondrial stress elicited by the mitochondrial neurotoxin 1-methyl-4-phenylpyridine (MPP+) within cultured DAergic cells. Genetic p23 knockdown was found to result in decreases in steady-state PHD2 protein and activity and reduced susceptibility to MPP+ neurotoxicity. Administration of the p23 inhibitor gedunin was also neuroprotective in these cells as well as in human induced pluripotent stem cell (iPSC)-derived neurons. Our data suggests that mitochondrial stress-mediated elevations in PHD2 interaction with the p23-hsp90 complex have detrimental effects on the survival of DAergic neurons, while p23 inhibition is neuroprotective. We propose that neurotoxic effects are tied to enhanced PHD2 stabilization by the hsp90-p23 chaperone complex that is abrogated by p23 inhibition. This demonstrates a novel connection between two independent pathways previously linked to PD, hsp90 and PHD2-HIF1α, which could have important implications for here-to-fore unexplored mechanisms underlying PD neuropathology. Published by Elsevier B.V.

Entities:  

Keywords:  Co-chaperone p23; Dopamine; Heat shock protein 90; Hypoxia-inducible factor 1 alpha; Mitochondria; Parkinson disease; Prolyl hydroxylase domain protein 2

Mesh:

Substances:

Year:  2018        PMID: 29471019      PMCID: PMC5857252          DOI: 10.1016/j.neuro.2018.02.012

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  45 in total

Review 1.  Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress.

Authors:  Ambreena Siddiq; Leila R Aminova; Rajiv R Ratan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

2.  Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Rebecca Banerjee; Lichuan Yang; Natalya A Smirnova; Dmitry M Hushpulian; Karen T Liby; Charlotte R Williams; Masayuki Yamamoto; Thomas W Kensler; Rajiv R Ratan; Michael B Sporn; M Flint Beal; Irina G Gazaryan; Bobby Thomas
Journal:  Antioxid Redox Signal       Date:  2012-08-13       Impact factor: 8.401

3.  Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling.

Authors:  Javorina Milosevic; Martina Maisel; Florian Wegner; Julia Leuchtenberger; Roland H Wenger; Manfred Gerlach; Alexander Storch; Johannes Schwarz
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

4.  The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways.

Authors:  Youngah Shin; Jochen Klucken; Cam Patterson; Bradley T Hyman; Pamela J McLean
Journal:  J Biol Chem       Date:  2005-04-21       Impact factor: 5.157

5.  Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.

Authors:  Todd R Flower; Liudmila S Chesnokova; Clifford A Froelich; Cheryl Dixon; Stephan N Witt
Journal:  J Mol Biol       Date:  2005-09-02       Impact factor: 5.469

6.  Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism.

Authors:  Francisco Ros-Bernal; Stéphane Hunot; Maria Trinidad Herrero; Sebastien Parnadeau; Jean-Christophe Corvol; Lixia Lu; Daniel Alvarez-Fischer; María Angeles Carrillo-de Sauvage; Françoise Saurini; Christiane Coussieu; Kiyoka Kinugawa; Annick Prigent; Günter Höglinger; Michel Hamon; François Tronche; Etienne C Hirsch; Sheela Vyas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-05       Impact factor: 11.205

7.  Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Authors:  Ambreena Siddiq; Issam A Ayoub; Juan C Chavez; Leila Aminova; Sapan Shah; Joseph C LaManna; Stephanie M Patton; James R Connor; Robert A Cherny; Irene Volitakis; Ashley I Bush; Ingrid Langsetmo; Todd Seeley; Volkmar Gunzler; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

8.  The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein.

Authors:  S Fabio Falsone; Andreas J Kungl; Angelika Rek; Roberto Cappai; Klaus Zangger
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

9.  Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.

Authors:  Xinru Li; Jenny Lee; Dee Parsons; Karen Janaurajs; David G Standaert
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

10.  Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Authors:  Lichuan Yang; Noel Y Calingasan; Bobby Thomas; Rajnish K Chaturvedi; Mahmoud Kiaei; Elizabeth J Wille; Karen T Liby; Charlotte Williams; Darlene Royce; Renee Risingsong; Eric S Musiek; Jason D Morrow; Michael Sporn; M Flint Beal
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more
  4 in total

Review 1.  Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases.

Authors:  Gouri Chopra; Shabnam Shabir; Sumaira Yousuf; Simran Kauts; Shahnawaz A Bhat; Ashiq H Mir; Mahendra P Singh
Journal:  Mol Neurobiol       Date:  2022-10-07       Impact factor: 5.682

Review 2.  Induced pluripotent stem cells for neural drug discovery.

Authors:  Atena Farkhondeh; Rong Li; Kirill Gorshkov; Kevin G Chen; Matthew Might; Steven Rodems; Donald C Lo; Wei Zheng
Journal:  Drug Discov Today       Date:  2019-01-18       Impact factor: 7.851

Review 3.  Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.

Authors:  Anastasiia Bohush; Paweł Bieganowski; Anna Filipek
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

Review 4.  Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.

Authors:  Lisha Wang; Liza Bergkvist; Rajnish Kumar; Bengt Winblad; Pavel F Pavlov
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.